title: Anti-albuminuric effects of the angiotensin AT1 receptor blocker telmisartan in hypertensive patients.
abstract: We evaluated the anti-hypertensive and anti-albuminuric effect of the angiotensin receptor blocker telmisartan alone and in combination with torasemide and amlodipine. Patients were hypertensive, both diabetics and non-diabetics with persistent microalbuminuria. Our primary endpoint was a change in microalbuminuria levels, while the secondary endpoints were changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine levels, and glomerular filtration rate.After the 16-week treatment period, the patients significantly reduced microalbuminuria levels (76.4 ± 52.4 μg/min; p < 0.001), SBP (16.4 ± 8.7 mmHg; p < 0.001) and DBP (17.7 ± 5.9 mmHg; p < 0.001). Both diabetics and non-diabetics showed an identical pattern of significance with respect to the whole population. Systolic blood pressure, DBP, and microalbuminuria were significantly reduced as a consequence of therapy, both in diabetics and non-diabetics.
authors.affiliation: Department of Nephrology - Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain. jrodperd@gobiernodecanarias.org
authors.forename: José C
authors.initials: JC
authors.lastname: Rodríguez-Pérez
authors.forename: Miguel A
authors.initials: MA
authors.lastname: García-Bello
authors.forename: Aránzazu
authors.initials: A
authors.lastname: Anabitarte-Prieto
authors.forename: Osmel
authors.initials: O
authors.lastname: Companioni
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Nóvoa-Mogollón
authors.forename: Saturnino
authors.initials: S
authors.lastname: Suárez-Ortega
authors.forename: Celia
authors.initials: C
authors.lastname: Plaza-Toledano
authors.forename: Francisco
authors.initials: F
authors.lastname: Rodríguez-Esparragón
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000419:Albuminuria / Q000188:drug therapy*; D017311:Amlodipine / Q000008:administration & dosage; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001562:Benzimidazoles / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D003928:Diabetic Nephropathies / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013449:Sulfonamides / Q000008:administration & dosage; D000077333:Telmisartan; D000077786:Torsemide; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D013449:Sulfonamides; D017311:Amlodipine; D003404:Creatinine; D000077333:Telmisartan; D000077786:Torsemide